

MICU Treatment Protocol

**Amiodarone (Cordarone)**

Indicators: Sustained severe ventricular tachycardia, supraventricular tachycardia, atrial fibrillations, ventricular fibrillation not controlled by first-line agents.

Contra-indications: Second or third degree AV block, bradycardia.

Adverse Effects: Flushing, edema, sinus arrest, hypotension, bradycardia, CHF, dysrhythmias, SA node dysfunction, nausea and vomiting, headache, dizziness, tremors, abdominal pain.

Administration: IV bolus 150 mg over 10 minutes (15 mg/min), then 360 mg over 6 hours (1 mg/min), then 540 mg over the remaining 18 hours (0.5 mg/min).

MICU Directives:

1. Follow generalized protocol for MICU transports.
2. Maintain drip per sending facility orders.
3. Discontinue if significant adverse effects occur.

MCA Approved	05/01	07/02		
Implement	05/01	01/03		